| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2970601 | The Journal of Heart and Lung Transplantation | 2013 | 9 Pages |
Abstract
Intravenous prostacyclin and combination therapy are not consistently used in the most seriously ill patients enrolled in REVEAL after being assessed as FC IV or at the time of death.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Harrison W. MD, Dave P. MS, Leslie A. PhD, Michael D. MD,